Avalglucosidase alfa
Therapetic Avalglucosidase alfa enzyme from the original Nexviadyme® commercial drug.
Reference Standard as Aliquots
Product Batch | Therapeutic Expiry Date
| Brand & Origin
| Amount per Aliquot
| Select Quantity | Discount | Price per Aliquot
| |
|---|---|---|---|---|---|---|---|
tbd; product is not in stock - minimum order quantity applies |
Nexviadyme® |
10 mg |
1.049,00 €
/aliquot
|
Biosimilars as Aliquots
Access Batch Specific Analytical Information
Evidentic’s Analytical Data Service includes a comprehensive array of methods to support the drug development process, including structure, aggregation, degree of isomerization, and N-glycans identification of the active pharmaceutical ingredient (API).
Product Information
Here you will find the product information for the reference product.
Nexviadyme® / Avalglucosidase alfa Reference Product
| Drug name | Nexviadyme® |
| INN | Avalglucosidase alfa |
| API type | Enzyme |
| Pharmacotherapeutic group | Not assigned yet |
| ATC code | Not assigned yet |
| Target of antibody | Lysosomal glycogen |
| General function | |
| Short description | Avalglucosidase alfa is indicated for long-term enzyme replacement therapy for the treatment of patients with Pompe disease (acid α-glucosidase deficiency). |
| Pharmacodynamic properties (Mechanism of action; Source EMA document) | Avalglucosidase alfa is a recombinant human acid α-glucosidase (rhGAA) that provides an exogenous source of GAA. Avalglucosidase alfa is a modification of alglucosidase alfa in which approximately 7 hexamannose structures each containing 2 terminal mannose-6-phosphate (bis-M6P) moieties are conjugated to oxidized sialic acid residues on alglucosidase alfa. Avalglucosidase alfa has a 15-fold increase in mannose-6-phosphate (M6P) moieties compared with alglucosidase alfa. Binding to M6P receptors on the cell surface has been shown to occur via carbohydrate groups on the GAA molecule, after which it is internalised and transported into lysosomes, where it undergoes proteolytic cleavage that results in increased enzymatic activity to degrade glycogen. |
| Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document) | Avalglucosidase alfa is a recombinant alpha-glucosidase (GAA) enzyme that catalyzes hydrolysis of glycogen. In clinical trials, avalglucosidase alfa reduced the levels of glycogen excreted in the urine of patients with Pompe disease, indicating that it effectively cleaved excess glycogen. Avalglucosidase alfa has significantly higher binding affinity for cation-independent mannose-6-phosphate receptor (CI-MPR) for cellular uptake and better muscle targeting than alglucosidase alfa. In GAA-deficient mice, avalglucosidase alfa reduced glycogen with more efficacy than alglucosidase alfa at an equivalent dose. |
| Original license holder | Sanofi B.V. Paasheuvelweg 25 1105 BP Amsterdam The Netherlands |
| Marketing authorisation numbers | EU/1/21/1579/001-4 |
| Marketing authorisation holder | Sanofi B.V. Paasheuvelweg 25 1105 BP Amsterdam The Netherlands |
| Name of the manufacturer of the biological active substance | Genzyme Flanders Cipalstraat 8 2440 Geel, Belgium |
| Name and address of the manufacturer(s) responsible for batch release | Genzyme Ireland Limited, IDA Industrial Park, Old Kilmeaden Road, Waterford, Ireland |
| Max shelf life | 4 years |
| Storage conditions | 2°C – 8°C |
| List of excipients | Histidine Histidine hydrochloride monohydrate Glycine Mannitol Polysorbate 80 |
Support
Do you have a question about the product? Reach out to our team using the form below – we’d be happy to help you!
Ready to simplify your sourcing?
Here’s how to get started:
Select Your Licensed Molecules
Browse our shop and choose the licensed molecule(s) you need. Don’t worry if you can’t find the molecule you’re looking for – we can source it for you!
Get a Quote
Receive a confidential, non-binding quote for the molecule(s) you choose.
Get Qualified & We Deliver
Complete our quick qualification process, place your order, and we’ll ship your molecule(s) within days.
Do you have a question you'd like to ask us?
Here’s how to get started:
